



Published in final edited form as:

Nat Rev Mol Cell Biol. 2009 July ; 10(7): 478–487. doi:10.1038/nrm2718.

Boveri revisited: Chromosomal instability, aneuploidy and tumorigenesis

Andrew J. Holland¹ and Don W. Cleveland^{1,*}

¹Ludwig Institute for Cancer Research and Department of Cellular and Molecular Medicine, University of California, 9500 Gilman Drive, San Diego, La Jolla, CA 92093-0670, USA

Preface

The mitotic checkpoint guards against chromosome missegregation and the production of aneuploid daughter cells. Aneuploidy is a common characteristic of tumor cells and has been proposed for over a century to drive tumor progression. However, recent evidence has revealed that although aneuploidy can increase the potential for cellular transformation, it also acts to antagonize tumorigenesis in certain genetic contexts. A clearer understanding of the tumor suppressive function of aneuploidy may reveal new avenues for anticancer therapy.

Introduction

Each time a cell divides it must accurately duplicate its genome and faithfully partition it into the daughter cells. If this process fails to occur accurately then the resulting daughters may inherit too many or too few chromosomes, a condition known as aneuploidy. Over a century ago the German zoologist Theodor Boveri described the effect of aneuploidy on organism development. Studying sea urchin embryos undergoing abnormal mitotic divisions, Boveri demonstrated that aneuploidy has a detrimental effect on cell and organism physiology¹. Drawing on this discovery and von Hansemann's observations of abnormal mitotic figures in tumor cells², Boveri proposed that an abnormal chromosome constitution may promote cancer³. Today it is clear that aneuploidy is a common genetic feature of solid human tumors⁴. However, whether aneuploidy is a cause or a consequence of malignant transformation remains hotly debated.

Part of the difficulty in studying the role of aneuploidy in cancer has stemmed from the complex and diverse array of chromosomal abnormalities found even among clinically similar tumors. Indeed, coupled with numerical changes in whole chromosomes, cancer cells also often display structural chromosomal alterations, including deletions, amplifications and translocations. Structural alterations of chromosomes are a well-established cause of cancer and thus, for the purpose of this Opinion article, we use aneuploidy to describe numerical alterations in whole chromosomes. Here, we review the pathways by which aneuploidy arises and consider the evidence suggesting a causative role for aneuploidy in the development of tumors, as well as surprising new evidence which shows aneuploidy can suppress tumorigenesis in certain genetic contexts and cell types⁵.

*To whom correspondence should be addressed. dcleveland@ucsd.edu.

The roads to aneuploidy

Weakening mitotic checkpoint signaling

Aneuploidy is often caused by errors in chromosome partitioning during mitosis. A surveillance mechanism known as the mitotic checkpoint (also known as spindle assembly checkpoint) is a primary guard against chromosome missegregation (Box 1)^{6, 7}. Under normal circumstances the mitotic checkpoint delays mitotic progression in response to a single unattached kinetochore⁸. However, if checkpoint signaling is compromised, cells can initiate anaphase before all chromosomes have established proper spindle attachments, leading to chromosome missegregation and subsequent aneuploidy (Figure 1A). An extensive search has uncovered altered expression or mutation of mitotic checkpoint components in a subset of aneuploid human cancers including, leukemias, breast, colorectal, ovarian and lung cancer⁴. In addition, germline mutations in the mitotic checkpoint component BubR1 have been identified in patients suffering from the rare genetic disorder Mosaic Variegated Aneuploidy (MVA), in which as many as 25% of cells in multiple tissues are aneuploid^{9, 10}. Nevertheless, mutated or altered expression of mitotic checkpoint genes account for, at most, a minor proportion of the aneuploidy observed in human tumors.

Defects in chromosome cohesion or attachment

To identify other mechanisms leading to aneuploidization, genes with putative functions in guarding against chromosome missegregation were systematically sequenced in a panel of aneuploid colorectal cancers¹¹. Surprisingly, 10 of the 11 mutations identified were in genes that directly contribute to sister chromatid cohesion, indicating that defects in the machinery-controlling sister chromatid cohesion may promote aneuploidy (Figure 1B). Consistently, overexpression of SEPARASE or SECURIN, two key regulators controlling the loss of chromatid cohesion, promotes aneuploidy and cellular transformation¹²⁻¹⁵. Chromosome missegregation may also arise from the improper attachment of kinetochores to spindle microtubules. This can occur when a single kinetochore attaches to microtubules emanating from both poles of the spindle, a situation known as merotelic attachment (Figure 1C)¹⁶. Since merotelically oriented kinetochores are attached and under tension, their presence does not continue to activate mitotic checkpoint signaling. Although merotelic attachments are usually corrected before entry into anaphase¹⁷, if they persist both sister chromatids may be missegregated towards the same pole (called chromosome non-disjunction) or lagging chromosomes may be left in the spindle midzone and excluded from both daughter nuclei^{18, 19}.

Multipolar spindles

A final source of aneuploidy arises when a cell containing more than two centrosomes enters mitosis (Figure 2A). The centrosome forms the poles of the mitotic spindle and cells possessing extra centrosomes can form multipolar spindles. If not corrected, a multipolar anaphase can produce three or more highly aneuploid daughter cells that are likely to be inviable (Figure 1D). Multipolar mitotic divisions are rare because in most cases extra centrosomes are clustered into two groups allowing bipolar spindles to form^{20, 21} (Box 2). While the progeny of these divisions are likely to survive, the passage through a multipolar intermediate prior to centrosomal clustering will increase the frequency of improper kinetochore-microtubule attachments, including merotelic orientations (Figure 1D), thereby promoting chromosome missegregation through a mechanism independent of multipolar divisions.

Aneuploidy and CIN

Some tumor cells are stably aneuploid, reflecting a transient chromosome missegregation event at some point in the development of the tumor leading to an abnormal karyotype that is stably propagated and inherited. More often, however, aneuploidy is a result of an underlying chromosomal instability (CIN), characterized by an increase in the rate of gains and losses of whole chromosomes during division²². Aneuploidy and CIN are not synonymous: while aneuploidy describes the state of having an abnormal chromosome number, CIN refers to an elevated *rate* of chromosome gain or loss. This is exemplified in Down's syndrome, a condition associated with widespread aneuploidy but not CIN.

For more than a decade the molecular mechanisms underlying CIN have remained unclear. Cells possessing CIN were originally reported to have an impaired ability to sustain a mitotic arrest in response to spindle toxins²³, leading to wide spread acceptance of the proposal that an attenuated mitotic checkpoint may be the primary cause of CIN⁶. This view is probably wrong. Direct measurements using live cell imaging to visualize mitosis have revealed that in response to spindle toxins, the duration of mitosis in CIN cells is at least as long as in chromosomally stable diploid cells²⁴. Moreover, CIN cells were not found to enter anaphase in the presence of misaligned chromosomes, demonstrating that at least in these cells, mitotic checkpoint dysfunction is not a primary cause of CIN^{24, 25}. Although CIN cells did not enter anaphase precociously, they did exhibit an increase in the incidence of lagging anaphase chromosomes, caused at least in part by unresolved merotelic attachments.

The underlying cause of increased malorientations in CIN cells has not been determined, but could be caused by an acquired defect in resolving merotelic orientations prior to anaphase or in spindle assembly. For example, the clustering of centrosomes in a multipolar mitotic spindle may increase the number of kinetochore mal-orientations ((Box 2 and Figure 1D). Recently, it was shown that reductions in kinetochore-microtubule turnover in early mitosis increase the frequency of kinetochore mal-orientations and chromosome missegregation²⁶. Remarkably, a modest increase in expression of either of a pair of kinetochore localized microtubule-depolymerizing enzymes substantially reduced the occurrence of lagging anaphase chromosomes and chromosome missegregation in CIN cells, suggesting a causal relationship between kinetochore-microtubule dynamics and CIN²⁶.

Aneuploidy facilitates tumor formation

The role of aneuploidy in tumorigenesis has been extensively studied in mouse models of mitotic checkpoint dysfunction. So far, conventional gene knockouts have been constructed for almost all known mitotic checkpoint genes, including *Mad1*, *Mad2*, *Bub1*, *Bub3*, *BubR1*, *Rae1* and *CENP-E*²⁷⁻³³. In addition, hypomorphic alleles expressing dramatically reduced levels of BUB1 and BUBR1 have also been generated^{34, 35}. While complete loss of these gene products results in early embryonic lethality, heterozygous and hypomorphic mice are viable and fertile. In all cases, mice with genetically reduced levels of mitotic checkpoint components display an increased level of aneuploidy and CIN in mouse embryonic fibroblasts (MEFs) and tissues^{27-30, 32, 34-37}. However, the degree of aneuploidy, including the proportion of aneuploid cells and the spectrum of chromosome losses and gains, varies depending on which gene product has been reduced and to what level (Table 1).

Downregulation of mitotic checkpoint components

In some instances, reduced expression of mitotic checkpoint components is associated with an increase in spontaneous cancer (Table 1). Specifically, *Mad1* and *Mad2* heterozygous mice develop lung tumors while *CENP-E* heterozygous animals show an increased

incidence of lung tumors and splenic lymphomas^{27, 28, 38}. The cancers formed in these animals are benign and occur late in life (<18 months), suggesting the acquisition of a transformed karyotype is a rare event that requires many consecutive generations of chromosome missegregation. In contrast, *Bub1* hypomorphic mice develop a wide array of lethal cancers including, lymphomas, lung and liver tumors³⁵. Nevertheless, in all situations where aneuploidy has been found to promote spontaneous tumorigenesis, tumors form in only a fraction of animals (Table 1), suggesting that the transformation of aneuploid cells relies upon the chance acquisition of additional, cooperating mutations in regulatory genes.

Several mitotic checkpoint deficient mice display a significantly elevated level of aneuploidy without an increase in spontaneous tumorigenesis, demonstrating that cancer is not an inescapable fate of aneuploidy^{29, 34, 35, 39-42}. Indeed, to date there is no direct correlation between the level of aneuploidy and the incidence of spontaneous tumor development. Indeed, *Bub3;Rae1* and *Rae1;Nup98* compound heterozygotes possess similar levels of aneuploidy to *Bub1* hypomorphic mice; however, unlike *Bub1* hypomorphs, *Bub3;Rae1* and *Rae1;Nup98* exhibit no increase in spontaneous tumor development (Table 1)^{35, 40, 42, 43}.

It remains unclear why a reduction in some mitotic checkpoint components drives spontaneous tumorigenesis while others do not. One possibility is that in addition to guarding against aneuploidy, some mitotic checkpoint proteins have other tumor suppressive roles. For example, BUB1 has recently been proposed to play a role in eliminating aneuploid cells from the population, which may explain the high tumor susceptibility of *Bub1* hypomorphic mice³⁵. Alternatively, loss of different mitotic checkpoint components may give rise to distinct types of aneuploidy that could have different effects on tumorigenesis. For instance, aneuploid splenocytes from mice with reduced levels of BUB1, BUBR1, BUB3 and RAE1 show both gain and losses of whole chromosomes^{29, 34, 35}, while *CENP-E* heterozygous animals show almost exclusive chromosome loss³⁸.

Although aneuploid *Bub1*, *BubR1*, *Bub3*, *Rae1* and *Rae1;Nup98* heterozygous animals fail to display an increase in spontaneous tumorigenesis, these mice are prone to carcinogen-induced tumors (Table 1)^{29, 35, 41}. This suggests that in these mouse models aneuploidy does not initiate cancer, but rather drives tumor formation in cases where mutations at oncogenic or tumor suppressor loci have already increased the potential for cellular transformation. Consistently, mutations in some tumor suppressor genes cooperate with aneuploidy to promote tumor progression. For example, reduced levels of BUBR1 promote an increase in lung tumors in mice lacking the p16 tumor suppressor⁴⁴ and a 10-fold increase in colon tumors in sensitized *APC^{Min/+}* animals³⁷ (*APC^{Min/+}* mice carry a heterozygous truncating mutation in the *APC* tumor suppressor resulting in the development of benign colon and intestinal tumors at an early age). Together, these data suggest that the mutations that cooperate with aneuploidy to promote tumor formation do not occur at a significantly frequency during the lifetime of laboratory mice.

Upregulation of mitotic checkpoint components

Paradoxically, inactivating mutations in mitotic checkpoint genes are rarely observed in human cancer, however, abnormally high expression is much more frequent⁴. Indeed, overexpression of MAD2 and the kinetochore component HEC1 are common in human tumors and elevated levels of these proteins are often associated with a poor prognosis. Increased expression of HEC1 has been shown to drive aneuploidy and an elevation in spontaneous lung and liver tumors in mice⁴⁵. In addition, conditional overexpression of MAD2 predisposes animals to a wide spectrum of early-onset, lethal tumors⁴⁶. Importantly, continued tumor growth does not remain dependent on expression of the MAD2 transgene, suggesting that once neoplastic transformation has occurred, excessive MAD2 is not

required for tumor maintenance. Surprisingly, MAD2 transgenic mice are considerably more tumor prone than mice with reduced levels of MAD2^{28, 46}. However, in addition to rampant aneuploidy, mice overexpressing MAD2 also show large-scale structural defects, including chromosomal breaks, fusions amplifications and interstitial deletions. Thus, it remains unclear whether it is aneuploidy or structural defects that are the primary cause of tumorigenesis in these animals.

Taken together, mouse models have unequivocally demonstrated that aneuploidy is capable of increasing the risk of neoplastic transformation, albeit aneuploidy *per se* acts to facilitate the development of tumors in a predisposed background. How aneuploidy does this remains unclear. One possibility is that aneuploidy may result in the duplication of a chromosome containing an oncogenic allele or the loss of a chromosome possessing the remaining wild type copy of a tumor suppressor gene (known as loss of heterozygosity (LOH)). Consistent with this hypothesis, aneuploidy caused by haploinsufficiency of Mad2 or Mad1;Mad2 has been shown to increase both the frequency and number of tumors in a *p53*^{+/-} background⁴⁷. By contrast, however, *Bub3* haploinsufficiency did not alter the rate or frequency of tumorigenesis in *p53* or *Rb1* heterozygous mice³⁹. While these studies appear contradictory, it is notable that the incidence of aneuploidy is considerably higher in *Mad2*^{+/-} compared with *Bub3*^{+/-} MEFs (Table 1). This suggests the difference in tumor susceptibility may be a result of a higher level of LOH in *Mad2* haploinsufficient mice.

An alternative explanation for aneuploidy's tumor promoting activity is that additional chromosomes help protect aneuploid cells against the effect of deleterious mutations in essential and haplo-insufficient genes. Aneuploidy may, therefore, allow cells to survive longer in the presence of ongoing DNA damage, allowing more time for cells to accumulate critical growth promoting and transforming mutations. Identifying the lesions that cooperate with aneuploidy to promote cellular transformation will be an important area for future research.

Doubling up: tetraploidy and cancer

While some aneuploid human cancers have minor imbalances in chromosome numbers, a substantial number also exhibit large-scale aneuploidy, often containing a near tetraploid number of chromosomes⁴. Tetraploidy can arise through a number of mechanisms, including cell fusion, mitotic slippage and cytokinesis failure (Figure 2A). In addition to a doubling of the chromosome content, tetraploid cells typically contain twice the normal complement of centrosomes. Supernumerary centrosomes promote aberrant mitotic divisions and chromosome missegregation at a high frequency and thus, tetraploidy is an inherently unstable state that acts as a catalyst to promote further aneuploidy and genomic instability ((Box 2)⁴⁸. Indeed, tetraploidy has been shown to initiate CIN and has been found to precede the development of CIN and aneuploidy in several cancers⁴⁹⁻⁵¹.

There is now compelling evidence to suggest that the uncontrolled proliferation of tetraploid cells can trigger cellular transformation and tumor formation. The most direct evidence came from the observation that tetraploid *p53*^{+/-} mouse cells initiate tumor formation when transplanted into immunocompromised mice, while isogenic diploid cells did not⁴⁸. Importantly, the tetraploid-derived tumors displayed large-scale numerical and structural chromosomal aberrations, demonstrating that tetraploidy can initiate massive genomic instability. Interestingly, cells derived from mice overexpressing MAD2 have a substantial increase in the number of tetraploid cells, which may explain the increase in structural chromosome aberrations and high tumor susceptibility of these animals⁴⁶.

Consistent with a causative role for tetraploidy in cancer, several established oncogenes and tumor suppressor genes have also been shown to induce tetraploidization. For instance,

AURORA A is frequently overexpressed in human cancers and increased levels have been shown to cause cytokinesis failure⁵². Overexpression of AURORA A in the mammary gland of mice leads to an increase in tetraploidization, CIN and the formation of mammary tumors⁵³. In addition, mutations in the *APC* tumor suppressor are commonly found in human colon cancers and have been shown to cause cytokinesis failure and tetraploidization in mice⁵⁴.

Aneuploidy can act as a tumor suppressor

Although aneuploidy has long been implicated in driving cancer, in certain cases aneuploidy can suppress tumorigenesis (Table 1). *CENP-E* haplo-insufficiency reduces the incidence of carcinogen-induced tumors and dramatically extends the survival of mice lacking the *p19^{ARF}* tumor suppressor³⁸. Moreover, mice heterozygous for *BubR1* develop ~50% fewer tumors in the sensitized *APC^{Min/+}* background³⁷, while deletion of *Securin* reduces the incidence of pituitary tumors by ~50% in *Rb* heterozygous animals⁵⁵ (admittedly, in this last case it remains unclear if tumor suppression results from increased levels of aneuploidy).

Tumor repression has also been observed in stably aneuploid mice that are trisomic for ~50% of the orthologue genes on human chromosome 21⁵⁶. One explanation for these observations is that exposure to carcinogens or loss of tumor suppressor function results in low levels of genetic damage and/or chromosome missegregation, which when combined with aneuploidy, drive rates of genetic instability above a threshold compatible with cell viability. Consistently, *p19^{ARF}*^{-/-} and carcinogen treated MEFs exhibit a level of aneuploidy that is exacerbated by *CENP-E* haploinsufficiency⁵. Moreover, aneuploidy and apoptosis is also increased in the intestines of *BubR1^{+/-}*; *APC^{Min/+}* mice, providing evidence that too much aneuploidy may promote cell death and inhibit tumor growth³⁷.

The Yin and Yang of aneuploidy in tumorigenesis

Unlike point mutations that only affect a small number of genes, the gain or loss of a single chromosome alters the transcription of hundreds of genes and has the capacity to disturb a large array of cellular processes. This imbalance imparts a stress that can hamper the growth of aneuploid cells. Indeed, yeast strains containing one or more additional chromosomes grow more slowly than their haploid counterparts. Moreover, mouse cells engineered to be trisomic for specific chromosomes exhibit a proliferation delay, as do human fibroblasts derived from individuals with Down's syndrome⁵⁷⁻⁵⁹. Consistently, when aneuploidy is introduced into a normally diploid cancer cell line, the aneuploid cells are outcompeted by diploid cells²⁵. Thus, under normal circumstances, aneuploidy may act as a barrier to suppress tumorigenesis by reducing the growth of preneoplastic cells.

If the majority of the karyotypes generated by random chromosome missegregation will confer a growth disadvantage to cells or cause lethality, how then can aneuploidy promote tumorigenesis in some contexts? One interesting possibility proposed by Amon and coworkers is that aneuploidy provides a selective pressure for the accumulation of additional mutations that allow cells to tolerate the adverse effects of chromosomal imbalances⁶⁰. The unbalanced gene expression caused by aneuploidy may increase the rate at which cells acquire the mutations necessary for their survival and proliferation. Once gained, these adaptations would unlock the oncogenic potential of aneuploidy, allowing cells to survive and continue to proliferate in the face of increased genomic instability.

Conclusions: context matters

A century after Boveri initially proposed aneuploidy to drive tumorigenesis an overriding message is now clear: aneuploidy is able to alter the course of tumor development.

However, whether it does so in a positive or negative manner depends upon the cell type and the genetic context. For example, while mice heterozygous for *CENP-E* exhibit an increase in the rate of spontaneous lung and spleen tumors, these animals demonstrate a decreased incidence of liver tumors³⁸. Moreover, Down's syndrome patients carrying an extra copy of chromosome 21 have a significant increase in hematological cancers, but a reduced incidence of solid tumors⁶¹⁻⁶³. Therefore, the effect of aneuploidy may not be driven by a particular combination of chromosomes *per se*, but rather by the specific interaction of the karyotype with the various genetic contexts and microenvironments found in different tissues. This explains why some tissues, such as lung epithelial cells, seem to have a higher propensity for malignant progression in aneuploid mice (Table 1). A clear goal for the future is to establish under which genetic contexts and cell types aneuploidy promotes or suppresses tumorigenesis.

Moreover, while current mouse modeling has predominantly focused on deregulation of mitotic checkpoint genes as a course for driving aneuploidy *in vivo*, checkpoint dysfunction does not appear to be a primary cause of CIN in human cancers. Therefore, new models of chromosomal instability that faithfully mimic the lesions and pathways frequently deregulated in aneuploid cancer cells are needed, especially models that can drive inducible or transient chromosomal instability, whose use may reveal novel therapeutic avenues to exploit the tumor suppressive effect of aneuploidy.

References

1. Boveri T. Ueber mehrpolige Mitosen als Mittel zur Analyse des Zellkerns. Verh Phys-med Ges Würzburg NF. 1902; 35:67–90.
2. Hansemann D. Ueber asymmetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung. Arch Pathol Anat Physiol Klin Medicin. 1980; 119:299–326.
3. Boveri T. Zur Frage der Entstehung maligner Tumoren. Fischer, Jena. 1914
4. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol. 2006; 18:658–67. [PubMed: 17046232]
5. Weaver BA, Cleveland DW. Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res. 2007; 67:10103–5. [PubMed: 17974949]
6. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005; 5:773–85. [PubMed: 16195750]
7. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol. 2007; 8:379–93. [PubMed: 17426725]
8. Rieder CL, Cole RW, Khodjakov A, Sluder G. The checkpoint delaying anaphase in response to chromosome monoorientation is mediated by an inhibitory signal produced by unattached kinetochores. J Cell Biol. 1995; 130:941–8. [PubMed: 7642709]
9. Hanks S, et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet. 2004; 36:1159–61. [PubMed: 15475955]
10. Matsuura S, et al. Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome. Am J Med Genet A. 2006; 140:358–67. [PubMed: 16411201]
11. Barber TD, et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci U S A. 2008; 105:3443–8. [PubMed: 18299561]
12. Zhang N, et al. Overexpression of Separase induces aneuploidy and mammary tumorigenesis. Proc Natl Acad Sci U S A. 2008; 105:13033–8. [PubMed: 18728194]
13. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997; 11:433–41. [PubMed: 9092795]
14. Yu R, Lu W, Chen J, McCabe CJ, Melmed S. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology. 2003; 144:4991–8. [PubMed: 12960092]

15. Zhang X, et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). *Mol Endocrinol*. 1999; 13:156–66. [PubMed: 9892021]
16. Cimini D. Merotelic kinetochore orientation, aneuploidy, and cancer. *Biochim Biophys Acta*. 2008; 1786:32–40. [PubMed: 18549824]
17. Cimini D, Moree B, Canman JC, Salmon ED. Merotelic kinetochore orientation occurs frequently during early mitosis in mammalian tissue cells and error correction is achieved by two different mechanisms. *J Cell Sci*. 2003; 116:4213–25. [PubMed: 12953065]
18. Cimini D, Fioravanti D, Salmon ED, Degrossi F. Merotelic kinetochore orientation versus chromosome mono-orientation in the origin of lagging chromosomes in human primary cells. *J Cell Sci*. 2002; 115:507–15. [PubMed: 11861758]
19. Cimini D, et al. Merotelic kinetochore orientation is a major mechanism of aneuploidy in mitotic mammalian tissue cells. *J Cell Biol*. 2001; 153:517–27. [PubMed: 11331303]
20. Brinkley BR. Managing the centrosome numbers game: from chaos to stability in cancer cell division. *Trends Cell Biol*. 2001; 11:18–21. [PubMed: 11146294]
21. Nigg EA. Origins and consequences of centrosome aberrations in human cancers. *Int J Cancer*. 2006; 119:2717–23. [PubMed: 17016823]
22. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. *Nature*. 1997; 386:623–7. [PubMed: 9121588]
23. Cahill DP, et al. Mutations of mitotic checkpoint genes in human cancers. *Nature*. 1998; 392:300–3. [PubMed: 9521327]
24. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimetabolic drugs. *Cancer Cell*. 2008; 14:111–22. [PubMed: 18656424]
25. Thompson SL, Compton DA. Examining the link between chromosomal instability and aneuploidy in human cells. *J Cell Biol*. 2008; 180:665–72. [PubMed: 18283116]
26. Bakhoun SF, Thompson SL, Manning AL, Compton DA. Genome stability is ensured by temporal control of kinetochore-microtubule dynamics. *Nat Cell Biol*. 2008
27. Iwanaga Y, et al. Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the incidence of tumors in mice. *Cancer Res*. 2007; 67:160–6. [PubMed: 17210695]
28. Michel LS, et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. *Nature*. 2001; 409:355–9. [PubMed: 11201745]
29. Babu JR, et al. Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. *J Cell Biol*. 2003; 160:341–53. [PubMed: 12551952]
30. Kalitsis P, Earle E, Fowler KJ, Choo KH. Bub3 gene disruption in mice reveals essential mitotic spindle checkpoint function during early embryogenesis. *Genes Dev*. 2000; 14:2277–82. [PubMed: 10995385]
31. Perera D, et al. Bub1 maintains centromeric cohesion by activation of the spindle checkpoint. *Dev Cell*. 2007; 13:566–79. [PubMed: 17925231]
32. Putkey FR, et al. Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. *Dev Cell*. 2002; 3:351–65. [PubMed: 12361599]
33. Wang Q, et al. BUBR1 deficiency results in abnormal megakaryopoiesis. *Blood*. 2004; 103:1278–85. [PubMed: 14576056]
34. Baker DJ, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. *Nat Genet*. 2004; 36:744–9. [PubMed: 15208629]
35. Jeganathan K, Malureanu L, Baker DJ, Abraham SC, van Deursen JM. Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. *J Cell Biol*. 2007; 179:255–67. [PubMed: 17938250]
36. Weaver BA, et al. Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss. *J Cell Biol*. 2003; 162:551–63. [PubMed: 12925705]
37. Rao CV, et al. Colonic tumorigenesis in BubR1^{+/-}-ApcMin⁺ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. *Proc Natl Acad Sci U S A*. 2005; 102:4365–70. [PubMed: 15767571]

38. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. *Cancer Cell*. 2007; 11:25–36. [PubMed: 17189716]
39. Kalitsis P, et al. Increased chromosome instability but not cancer predisposition in haploinsufficient Bub3 mice. *Genes Chromosomes Cancer*. 2005; 44:29–36. [PubMed: 15898111]
40. Baker DJ, et al. Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. *J Cell Biol*. 2006; 172:529–40. [PubMed: 16476774]
41. Dai W, et al. Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. *Cancer Res*. 2004; 64:440–5. [PubMed: 14744753]
42. Jeganathan KB, Malureanu L, van Deursen JM. The Rae1-Nup98 complex prevents aneuploidy by inhibiting securin degradation. *Nature*. 2005; 438:1036–9. [PubMed: 16355229]
43. Jeganathan KB, Baker DJ, van Deursen JM. Securin associates with APCcdh1 in prometaphase but its destruction is delayed by Rae1 and Nup98 until the metaphase/anaphase transition. *Cell Cycle*. 2006; 5:366–70. [PubMed: 16479161]
44. Baker DJ, et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. *Nat Cell Biol*. 2008; 10:825–36. [PubMed: 18516091]
45. Diaz-Rodriguez E, Sotillo R, Schwartzman JM, Benzra R. Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. *Proc Natl Acad Sci U S A*. 2008; 105:16719–24. [PubMed: 18940925]
46. Sotillo R, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. *Cancer Cell*. 2007; 11:9–23. [PubMed: 17189715]
47. Chi YH, Ward JM, Cheng LI, Yasunaga J, Jeang KT. Spindle assembly checkpoint and p53 deficiencies cooperate for tumorigenesis in mice. *Int J Cancer*. 2008
48. Fujiwara T, et al. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. *Nature*. 2005; 437:1043–7. [PubMed: 16222300]
49. Galipeau PC, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. *Proc Natl Acad Sci U S A*. 1996; 93:7081–4. [PubMed: 8692948]
50. Olaharski AJ, et al. Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. *Carcinogenesis*. 2006; 27:337–43. [PubMed: 16123119]
51. Ornitz DM, Hammer RE, Messing A, Palmiter RD, Brinster RL. Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. *Science*. 1987; 238:188–93. [PubMed: 2821617]
52. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53^{-/-} cells. *EMBO J*. 2002; 21:483–92. [PubMed: 11847097]
53. Wang X, et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. *Oncogene*. 2006; 25:7148–58. [PubMed: 16715125]
54. Caldwell CM, Green RA, Kaplan KB. APC mutations lead to cytokinetic failures in vitro and tetraploid genotypes in Min mice. *J Cell Biol*. 2007; 178:1109–20. [PubMed: 17893240]
55. Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S. Pituitary hypoplasia in Pttg^{+/-} mice is protective for Rb^{+/-} pituitary tumorigenesis. *Mol Endocrinol*. 2005; 19:2371–9. [PubMed: 15919720]
56. Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. *Nature*. 2008; 451:73–5. [PubMed: 18172498]
57. Williams BR, et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. *Science*. 2008; 322:703–9. [PubMed: 18974345]
58. Segal DJ, McCoy EE. Studies on Down's syndrome in tissue culture. I. Growth rates and protein contents of fibroblast cultures. *J Cell Physiol*. 1974; 83:85–90. [PubMed: 4273197]
59. Torres EM, Williams BR, Amon A. Aneuploidy: cells losing their balance. *Genetics*. 2008; 179:737–46. [PubMed: 18558649]
60. Torres EM, et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. *Science*. 2007; 317:916–24. [PubMed: 17702937]

61. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. *Lancet*. 2002; 359:1019–25. [PubMed: 11937181]
62. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. *Lancet*. 2000; 355:165–9. [PubMed: 10675114]
63. Satge D, et al. A tumor profile in Down syndrome. *Am J Med Genet*. 1998; 78:207–16. [PubMed: 9677053]
64. Buffin E, Emre D, Karess RE. Flies without a spindle checkpoint. *Nat Cell Biol*. 2007; 9:565–72. [PubMed: 17417628]
65. Hoyt MA, Totis L, Roberts BT. *S. cerevisiae* genes required for cell cycle arrest in response to loss of microtubule function. *Cell*. 1991; 66:507–17. [PubMed: 1651171]
66. Li R, Murray AW. Feedback control of mitosis in budding yeast. *Cell*. 1991; 66:519–31. [PubMed: 1651172]
67. Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. *Cell*. 2000; 101:635–45. [PubMed: 10892650]
68. Kitagawa R, Rose AM. Components of the spindle-assembly checkpoint are essential in *Caenorhabditis elegans*. *Nat Cell Biol*. 1999; 1:514–21. [PubMed: 10587648]
69. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. *Proc Natl Acad Sci U S A*. 2004; 101:8699–704. [PubMed: 15159543]
70. Kulukian A, Han JS, Cleveland DW. Unattached kinetochores catalyze production of an anaphase inhibitor that requires a Mad2 template to prime Cdc20 for BubR1 binding. *Dev Cell*. 2009; 16:105–17. [PubMed: 19154722]
71. Holland AJ, Taylor SS. Many faces of separase regulation. *SEB Exp Biol Ser*. 2008; 59:99–112. [PubMed: 18368920]
72. Basto R, et al. Centrosome amplification can initiate tumorigenesis in flies. *Cell*. 2008; 133:1032–42. [PubMed: 18555779]
73. Yang Z, Loncarek J, Khodjakov A, Rieder CL. Extra centrosomes and/or chromosomes prolong mitosis in human cells. *Nat Cell Biol*. 2008; 10:748–51. [PubMed: 18469805]
74. Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, Saunders WS. Spindle multipolarity is prevented by centrosomal clustering. *Science*. 2005; 307:127–9. [PubMed: 15637283]
75. Basto R, et al. Flies without centrioles. *Cell*. 2006; 125:1375–86. [PubMed: 16814722]
76. Kwon M, et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. *Genes Dev*. 2008; 22:2189–203. [PubMed: 18662975]
77. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA. The Polo kinase Plk4 functions in centriole duplication. *Nat Cell Biol*. 2005; 7:1140–6. [PubMed: 16244668]
78. Peloponese JM Jr, Haller K, Miyazato A, Jeang KT. Abnormal centrosome amplification in cells through the targeting of Ran-binding protein-1 by the human T cell leukemia virus type-1 Tax oncoprotein. *Proc Natl Acad Sci U S A*. 2005; 102:18974–9. [PubMed: 16365316]
79. Wang X, et al. sSgo1, a major splice variant of Sgo1, functions in centriole cohesion where it is regulated by Plk1. *Dev Cell*. 2008; 14:331–41. [PubMed: 18331714]
80. Wang XX, Liu R, Jin SQ, Fan FY, Zhan QM. Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line. *Cell Res*. 2006; 16:356–66. [PubMed: 16617331]




Figure 1. Pathways to aneuploidization

There are several pathways by which cells may gain or lose chromosomes during mitosis. **A.** Defects in mitotic checkpoint signaling. A weakened mitotic checkpoint may allow cells to enter anaphase in the presence of unattached or misaligned chromosomes. As a consequence, both copies of one chromosome may be deposited into a single daughter cell. **B.** Cohesion defects. If sister chromatid cohesion is lost prematurely or persists during anaphase then chromosomes may be missegregated. **C.** Merotelic attachment. One kinetochore may attach to microtubules from both poles of the spindle. If these attachments persist into anaphase then lagging chromatid pairs may be missegregated or excluded from both daughter cells during cytokinesis. **D.** Multipolar mitotic divisions. Cells possessing more than two centrosomes may form multiple spindle poles during mitosis. If this defect is not corrected, then a multipolar division will occur resulting in the production of highly aneuploid and often inviable daughter cells. Often, however, centrosomes in multipolar spindles cluster into two groups to allow cells to divide in a bipolar fashion. Centrosome clustering will increase the formation of incorrect kinetochore-microtubule attachments (such as merotelic attachments). Extra centrosomes are thus, capable of driving low rates of chromosome missegregation through a mechanism independent of multipolar divisions.




Figure 2. Pathways to acquiring extra centrosomes


The centrosome consists of a pair of connected centrioles surrounded by the pericentriolar material (PCM). There are two major mechanisms by which cells can gain extra centrosomes. **A.** Centrosome amplification. Defects in the processes controlling centriole replication can lead to centriole overduplication, which results in multiple centrosomes in the next cell cycle. This process can occur when PLK4, a regulator of centriole biogenesis, is overexpressed^{72, 77}. Impairment of centrosome structure can cause fragmentation of the pericentriolar material. The acentriolar fragments can then serve to nucleate microtubules and create multipolar spindles. This has been found to occur following cellular infection with the human T cell lymphotropic virus Type 1 (HTLV-1)⁷⁸. Finally, defects in centriole cohesion can lead to the separation of paired centrioles before the completion of chromosome segregation, creating multiple microtubule nucleating foci. Cells with reduced levels of *sSgo1* have been shown to lose centriole cohesion prematurely⁷⁹. **B.** Cells become tetraploid. This can occur following cell-cell fusion or after cytokinesis failure. Alternatively, cells may skip mitosis altogether and endoreduplicate or “slip” out of mitosis and progress into the next cell cycle without undergoing anaphase or cytokinesis. In all these situations G1 tetraploid cells are created with two centrosomes that are duplicated during the next cell cycle.

Box 1. The mitotic checkpoint: a safeguard to protect against aneuploidy

The microtubule organizing center of the cell, the centrosome, is duplicated during S phase and separates at the beginning of mitosis. Microtubules nucleated by the centrosomes overlap to form a bilaterally symmetrical mitotic spindle, with each of the spindle poles organized around a single centrosome. Chromosomes attach to spindle microtubules at specialized proteinaceous structures known as kinetochores, which are assembled during mitosis upon centromeric chromatin. To ensure microtubules will pull sister chromatids to opposite sides of the cell, kinetochores of duplicated chromosomes must attach to microtubules emanating from opposite spindle poles, a state known as bi-orientation. Errors in this process lead to chromosome missegregation and the production of aneuploid daughter cells.

To guard against chromosome missegregation cells have evolved a surveillance mechanism known as the mitotic checkpoint (also known as spindle assembly checkpoint)⁷, which acts to delay the onset of anaphase until all chromosomes are properly attached and bi-oriented on the microtubule spindle⁶. In some organisms, such as yeast and flies, the mitotic checkpoint is not essential for viability⁶⁴⁻⁶⁶. In mammals, however, inactivation of the mitotic checkpoint leads to massive chromosome missegregation, cell autonomous killing and early embryonic lethality^{28, 30, 67-69}.

Core components of the mitotic checkpoint machinery include MAD1, MAD2, BUB1, BUBR1, BUB3 and CENP-E. These proteins localize to unattached or maloriented kinetochores, which in turn catalytically generate a diffusible signal⁷⁰ that inhibits CDC20 mediated activation of an E3 ubiquitin ligase, the Anaphase Promoting Complex/Cyclosome (APC/C). SEPARASE, the protease that cleaves the cohesins holding sister chromatids together, is inhibited by the binding of SECURIN or CYCLIN B⁷¹. Following attachment and alignment of all the chromosomes at metaphase, the checkpoint signal is silenced and the APC/C ubiquitylates and targets SECURIN and CYCLIN B for proteasome mediated destruction, thereby initiating anaphase. At the same time, the degradation of CYCLIN B inactivates CDK1 promoting mitotic exit.



Box 2. Centrosome amplification in cancer

In addition to numerical alterations in chromosomes, cancer cells frequently exhibit an amplification of centrosome number²¹. Extra centrosomes can lead to the formation of multiple spindle poles during mitosis resulting in the unequal distribution of chromosomes and the production of aneuploid daughter cells. This has led to the proposal that centrosome amplification may be a driving force behind genomic instability and tumorigenesis³. A direct test of the role of centrosome amplification in cancer was recently performed in the fly⁷². Remarkably, flies possessing extra centrosomes in ~60% of somatic cells were overtly normal and exhibited no dramatic increase in genetic instability. Nevertheless, larval brain cells with extra centrosomes generated metastatic tumors when transplanted into the abdomen of host flies, demonstrating that centrosome amplification can initiate tumorigenesis⁷².

The observation that cells from flies and human cancers proliferate normally in the presence of extra centrosomes is consistent with previous studies indicating cells have evolved pathways to minimize the damaging effect of centrosome amplification²⁰. At least three mechanisms are known to exist. First, centrosomes are clustered into two groups to allow division to occur in a bipolar fashion⁷³⁻⁷⁵. Second, centrosomes are inactivated such that they no longer nucleate microtubules and participate in spindle formation⁷². Finally, the mitotic checkpoint is activated by the unstable/incorrect microtubule attachments formed in multipolar mitotic spindles^{72, 73, 76}. This acts to delay cells in mitosis and provide additional time to cluster and inactivate centrosomes to enable a bipolar spindle to form. Recently, it has been shown that blocking processes that suppress the formation of multipolar spindles can selectively kill cells with amplified centrosomes, providing a possible therapeutic avenue for the treatment of cancer cells with supernumerary centrosomes⁷⁶.

Table 1

Context dependent roles of aneuploidy in tumorigenesis

Mouse Genotype	% Aneuploidy		Tumorigenesis		Comments/Ref
	MEFs (Cont)	Spleen (Cont)	Spontaneous	Carcinogen-induced	
Contexts in which aneuploidy promotes tumorigenesis					
<i>Aneuploid mouse models showing an increase in spontaneous tumorigenesis</i>					
<i>Mad1</i> ^{+/-}	ND	ND	24% develop tumors	ND	27
<i>Mad2</i> ^{+/-}	57(16)	ND	28% develop lung tumors	ND	28
<i>Bub1</i> ^{H/H}	35(7)	35(1)	48% develop lethal tumors	ND	34
<i>CENP-E</i> ^{+/-}	36(18)	35(10)	20% develop spleen and lung tumors	See Below	38
<i>BubR1</i> ^{+/-} ; <i>APC</i> ^{Min/+}	65(14)	ND	<i>BubR1</i> ^{+/-} ; <i>APC</i> ^{Min/+} show a 10 fold increase in colon tumors relative to <i>APC</i> ^{Min/+}	ND	37
<i>BubR1</i> ^{H/H} ; <i>p16</i> ^{-/-}	ND	ND	<i>BubR1</i> ^{H/H} ; <i>p16</i> ^{-/-} show increased lung tumors relative to <i>p16</i> ^{-/-}	ND	44
<i>Aneuploid mouse models showing an increase in carcinogen induced tumors</i>					
<i>Bub1</i> ^{+/-}	14(7)	16(1)	Normal	DMBA-induced	35
<i>Bub3</i> ^{+/-}	19(9)	9(0)	Normal	DMBA-induced	29
	42(35)	ND	Normal	ND	39
<i>Rae1</i> ^{+/-}	19(9)	9(0)	Normal	DMBA-induced	29
<i>Bub3</i> ^{+/-} ; <i>Rae1</i> ^{+/-}	41(9)	37(0)	Normal	DMBA-induced	Premature aging ^{29, 40}
<i>Rae1</i> ^{+/-} ; <i>Nup98</i> ^{+/-}	37(9)	32(0)	Normal	DMBA-induced	42, 43
<i>BubR1</i> ^{+/-}	14(9)	0(0)	Normal	DMBA-induced	34, 40, 33, 37
	61(14)	ND	ND	Azoxymethane-induced	
<i>BubR1</i> ^{H/H}	36(9)	15(0)	Normal	DMBA-induced	Premature aging ³⁸
<i>Aneuploid mouse models with overexpressed mitotic components</i>					
<i>Mad2</i> OE	53(5)	ND	50% develop tumors	ND	Increase in structural chromosomal alterations and the proportion of tetraploid cells ⁴⁶
<i>Hec1</i> OE	31(16)	ND	40% develop tumors	ND	45
<i>Aurora A</i> OE	ND	ND	40% developed mammary tumors	ND	<i>Aurora A</i> is overexpressed specifically in the mammary gland ⁸⁰
Contexts in which aneuploidy suppresses tumorigenesis					
<i>CENP-E</i> ^{+/-}	36(18)	35(10)	50% decrease in Liver tumors	DMBA-reduced	38

Mouse Genotype	% Aneuploidy		Tumorigenesis	Carcinogen-induced	Comments/Ref
	MEFs (Cont)	Spleen (Cont)			
<i>CENP-E^{+/-};p19^{ARF}^{-/-}</i>	ND	ND	Spontaneous <i>CENP-E^{+/-};p19^{ARF}^{-/-}</i> have a 93 day increase in survival relative to <i>p19^{ARF}^{-/-}</i> .	ND	38
<i>BubR1^{+/-};APC^{Min/+}</i>	65(14)	ND	<i>BubR1^{+/-};APC^{Min/+}</i> show a 50% decrease in small intestine tumors relative to <i>APC^{Min/+}</i> .	ND	37
Ts65Dn; <i>APC^{Min/+}</i>	100% *	100% *	Ts65Dn; <i>APC^{Min/+}</i> show a 44% decrease in small intestine tumors relative to <i>APC^{Min/+}</i> .	ND	*Ts65Dn mice are trisomic for ~50% of the orthologous genes on human chr21. ⁵⁶
<i>Pitg^{-/-};Rb^{+/-}</i>	ND	ND	<i>Pitg^{-/-};Rb^{+/-}</i> mice have a 56% decrease in pituitary tumors relative to <i>Rb^{+/-}</i> .	ND	55

H = hypomorph allele; - = null allele; + = wild type allele; Cont = Control; OE = over-expression; ND = Not determined; DMBA = 7,12-Dimethylbenz[*a*]anthracene